ELCC 2023 | Multimodality treatment and alternative endpoints in lung cancer at ELCC 2023

Paul Van Schil, MD, PhD, University Hospital Antwerp, Edegem, Belgium, gives an overview of his personal highpoints from European Lung Cancer Congress (ELCC) 2023 including presentations on the integration of surgery into multimodality treatment, as well as thought-provoking discussions on the advantages and disadvantages of induction versus adjuvant therapy. Dr Van Schil also discusses the major advances in alternative endpoints and questions whether complete pathological response and major pathological response may potentially serve as suitable surrogates for disease free survival (DFS) and overall survival (OS). This interview took place at ELCC 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.